-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Insider Selling: MiMedx Group, Inc. (NASDAQ:MDXG) Insider Sells 19,000 Shares of Stock
Insider Selling: MiMedx Group, Inc. (NASDAQ:MDXG) Insider Sells 19,000 Shares of Stock
MiMedx Group, Inc. (NASDAQ:MDXG – Get Rating) insider Robert Benjamin Stein sold 19,000 shares of MiMedx Group stock in a transaction on Monday, September 12th. The shares were sold at an average price of $3.44, for a total transaction of $65,360.00. Following the completion of the sale, the insider now directly owns 287,002 shares of the company's stock, valued at $987,286.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Robert Benjamin Stein also recently made the following trade(s):
Get MiMedx Group alerts:- On Friday, August 12th, Robert Benjamin Stein sold 8,503 shares of MiMedx Group stock. The shares were sold at an average price of $4.04, for a total transaction of $34,352.12.
- On Thursday, August 4th, Robert Benjamin Stein sold 19,500 shares of MiMedx Group stock. The shares were sold at an average price of $3.62, for a total transaction of $70,590.00.
- On Tuesday, June 28th, Robert Benjamin Stein sold 14,600 shares of MiMedx Group stock. The shares were sold at an average price of $3.47, for a total transaction of $50,662.00.
MiMedx Group Price Performance
Shares of NASDAQ MDXG remained flat at $3.46 during mid-day trading on Wednesday. 755,400 shares of the stock were exchanged, compared to its average volume of 536,099. The company has a market capitalization of $393.09 million, a PE ratio of -13.84 and a beta of 1.75. The business has a fifty day moving average of $3.68 and a 200-day moving average of $3.98. MiMedx Group, Inc. has a 52-week low of $3.04 and a 52-week high of $8.69. The company has a debt-to-equity ratio of 586.91, a quick ratio of 3.17 and a current ratio of 3.53.
MiMedx Group (NASDAQ:MDXG – Get Rating) last released its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.05). The company had revenue of $66.88 million for the quarter, compared to analyst estimates of $65.07 million. Equities research analysts anticipate that MiMedx Group, Inc. will post -0.29 earnings per share for the current fiscal year.Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Point72 Hong Kong Ltd purchased a new position in MiMedx Group during the fourth quarter worth about $41,000. Russell Investments Group Ltd. purchased a new position in MiMedx Group during the second quarter worth about $28,000. Spinnaker Investment Group LLC purchased a new position in MiMedx Group during the fourth quarter worth about $47,000. Tiedemann Advisors LLC purchased a new position in MiMedx Group during the first quarter worth about $49,000. Finally, E Fund Management Co. Ltd. purchased a new position in MiMedx Group during the first quarter worth about $50,000. 60.86% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of brokerages have recently issued reports on MDXG. HC Wainwright reduced their price objective on shares of MiMedx Group from $8.50 to $8.00 and set a "buy" rating for the company in a report on Wednesday, September 7th. StockNews.com cut shares of MiMedx Group from a "buy" rating to a "hold" rating in a report on Friday, September 9th.
About MiMedx Group
(Get Rating)
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
Further Reading
- Get a free copy of the StockNews.com research report on MiMedx Group (MDXG)
- Can Health Drink Maker Celsius Outrun Its Monster Rival?
- Four Cheap Stocks With Interesting Insider Activity
- Is Lyft Going To Make It As Acquisition Rumors Swirl?
- It's Time To Embrace Another 25% Decline In The S&P 500
- Is Five Below Trying to Punch Too High?
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.
MiMedx Group, Inc. (NASDAQ:MDXG – Get Rating) insider Robert Benjamin Stein sold 19,000 shares of MiMedx Group stock in a transaction on Monday, September 12th. The shares were sold at an average price of $3.44, for a total transaction of $65,360.00. Following the completion of the sale, the insider now directly owns 287,002 shares of the company's stock, valued at $987,286.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
MIMEDX集团(纳斯达克代码:MDXG-GET Rating)内部人士罗伯特·本杰明·斯坦在9月12日(星期一)的交易中出售了19,000股MIMEX集团股票。这些股票以3.44美元的平均价格出售,总成交金额为65,360.00美元。出售完成后,这位内部人士现在直接持有该公司287,002股股票,价值987,286.88美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可通过以下链接获得。
Robert Benjamin Stein also recently made the following trade(s):
罗伯特·本杰明·斯坦最近还进行了以下交易:
- On Friday, August 12th, Robert Benjamin Stein sold 8,503 shares of MiMedx Group stock. The shares were sold at an average price of $4.04, for a total transaction of $34,352.12.
- On Thursday, August 4th, Robert Benjamin Stein sold 19,500 shares of MiMedx Group stock. The shares were sold at an average price of $3.62, for a total transaction of $70,590.00.
- On Tuesday, June 28th, Robert Benjamin Stein sold 14,600 shares of MiMedx Group stock. The shares were sold at an average price of $3.47, for a total transaction of $50,662.00.
- 8月12日,星期五,罗伯特·本杰明·斯坦出售了8,503股MiMedx集团股票。这些股票的平均价格为4.04美元,总成交金额为34,352.12美元。
- 8月4日,星期四,罗伯特·本杰明·斯坦出售了19,500股MiMedx集团股票。这些股票以3.62美元的平均价格出售,总成交金额为70,590.00美元。
- 6月28日,星期二,罗伯特·本杰明·斯坦出售了14,600股MiMedx集团股票。这些股票以3.47美元的平均价格出售,总成交金额为50,662.00美元。
MiMedx Group Price Performance
MiMedx集团性价比
Shares of NASDAQ MDXG remained flat at $3.46 during mid-day trading on Wednesday. 755,400 shares of the stock were exchanged, compared to its average volume of 536,099. The company has a market capitalization of $393.09 million, a PE ratio of -13.84 and a beta of 1.75. The business has a fifty day moving average of $3.68 and a 200-day moving average of $3.98. MiMedx Group, Inc. has a 52-week low of $3.04 and a 52-week high of $8.69. The company has a debt-to-equity ratio of 586.91, a quick ratio of 3.17 and a current ratio of 3.53.
周三午盘交易中,纳斯达克MDXG的股价持平于3.46美元。该股成交75.54万股,而其平均成交量为536,099股。该公司市值为3.9309亿美元,市盈率为-13.84,贝塔系数为1.75。该业务的50日移动均线切入位在3.68美元,200日移动均线切入位在3.98美元。MiMedx Group,Inc.的52周低点为3.04美元,52周高位为8.69美元。该公司的负债权益比率为586.91,速动比率为3.17%,流动比率为3.53%。
Institutional Inflows and Outflows
机构资金流入和流出
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Point72 Hong Kong Ltd purchased a new position in MiMedx Group during the fourth quarter worth about $41,000. Russell Investments Group Ltd. purchased a new position in MiMedx Group during the second quarter worth about $28,000. Spinnaker Investment Group LLC purchased a new position in MiMedx Group during the fourth quarter worth about $47,000. Tiedemann Advisors LLC purchased a new position in MiMedx Group during the first quarter worth about $49,000. Finally, E Fund Management Co. Ltd. purchased a new position in MiMedx Group during the first quarter worth about $50,000. 60.86% of the stock is currently owned by hedge funds and other institutional investors.
对冲基金和其他机构投资者最近增持或减持了该公司的股份。Point72 Hong Kong Ltd在第四季度购买了MiMedx Group的新头寸,价值约41,000美元。罗素投资集团有限公司在第二季度购买了MiMedx集团价值约28,000美元的新头寸。Spinnaker Investment Group LLC在第四季度购买了MiMedx Group的新头寸,价值约4.7万美元。Tiedemann Advisors LLC在第一季度购买了MiMedx Group的一个新头寸,价值约4.9万美元。最后,易方达基金管理有限公司在第一季度购买了MiMedx集团价值约5万美元的新头寸。60.86%的股票目前由对冲基金和其他机构投资者持有。
Analyst Ratings Changes
分析师评级发生变化
A number of brokerages have recently issued reports on MDXG. HC Wainwright reduced their price objective on shares of MiMedx Group from $8.50 to $8.00 and set a "buy" rating for the company in a report on Wednesday, September 7th. StockNews.com cut shares of MiMedx Group from a "buy" rating to a "hold" rating in a report on Friday, September 9th.
多家券商近期发布了关于MDXG的报告。在9月7日星期三的一份报告中,HC Wainwright将MiMedx Group的股票目标价从8.50美元下调至8.00美元,并为该公司设定了“买入”评级。在9月9日星期五的一份报告中,StockNews.com将MiMedx Group的股票评级从“买入”下调至“持有”。
About MiMedx Group
关于MiMedx集团
(Get Rating)
(获取评级)
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
MiMedx Group,Inc.为医疗保健的各个部门开发和分销同种异体胎盘组织移植。它利用其专利和专有的PURION工艺处理人类胎盘组织,以生产保留组织固有生物学特性和调节蛋白的同种异体移植物。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on MiMedx Group (MDXG)
- Can Health Drink Maker Celsius Outrun Its Monster Rival?
- Four Cheap Stocks With Interesting Insider Activity
- Is Lyft Going To Make It As Acquisition Rumors Swirl?
- It's Time To Embrace Another 25% Decline In The S&P 500
- Is Five Below Trying to Punch Too High?
- 免费获取StockNews.com关于MiMedx集团的研究报告(MDXG)
- 健康饮料制造商Celsius能否超越其Monster竞争对手?
- 具有有趣内幕活动的四只廉价股票
- 随着收购传言的甚嚣尘上,Lyft能否成功?
- 现在是时候接受标准普尔500指数再下跌25%的时候了
- 下面的五个是不是打得太高了?
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.
接受MiMedx集团日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收MiMedx集团和相关公司的最新新闻和分析师评级的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧